uniQure N.V. $QURE Shares Newly Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 216,197 shares of the biotechnology company’s stock, valued at approximately $5,223,000. uniQure makes up 1.0% of Privium Fund Management B.V.’s investment portfolio, making the stock its 22nd largest position.

Other institutional investors and hedge funds have also modified their holdings of the company. Orbimed Advisors LLC grew its position in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the period. Two Seas Capital LP acquired a new stake in uniQure during the 3rd quarter worth approximately $31,988,000. Assenagon Asset Management S.A. lifted its stake in uniQure by 249.9% in the second quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock valued at $23,653,000 after buying an additional 366,781 shares in the last quarter. Siren L.L.C. bought a new position in uniQure in the first quarter valued at approximately $16,350,000. Finally, Maverick Capital Ltd. boosted its holdings in shares of uniQure by 5.4% in the first quarter. Maverick Capital Ltd. now owns 697,640 shares of the biotechnology company’s stock valued at $11,406,000 after buying an additional 35,820 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Stock Up 3.3%

uniQure stock traded up $0.69 during midday trading on Friday, reaching $21.70. The stock had a trading volume of 1,172,882 shares, compared to its average volume of 1,937,432. The firm’s fifty day simple moving average is $31.86 and its 200-day simple moving average is $29.68. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $51.72. The stock has a market capitalization of $1.51 billion, a P/E ratio of -6.18 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The firm had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $6.17 million. As a group, analysts expect that uniQure N.V. will post -3.81 EPS for the current fiscal year.

Analyst Ratings Changes

QURE has been the subject of several research reports. UBS Group began coverage on shares of uniQure in a research report on Thursday, October 15th. They set a “buy” rating and a $48.00 price objective for the company. William Blair upgraded shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings raised shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $56.83.

uniQure Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.